|
1) Sugauchi F, Orito E, Ohno T, et al. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res. 2006; 36: 107-14
|
|
|
|
2) Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology. 2006; 44: 326-34
|
|
|
|
|
|
3) Chihara N, Arase Y, Suzuki F, et al. Prolonged hepatitis after acute infection with genotype H hepatitis B virus. Intern Med. 2007; 46: 1847-51
|
|
|
|
|
|
4) Kumagai I, Abe K, Oikawa T, et al. A male patient with severe acute hepatitis who was domestically infected with a genotype H hepatitis B virus in Iwate, Japan. J Gastroenterol. 2007; 42: 168-75
|
|
|
|
|
|
5) 玉田陽子, 矢野公士, 小松達司, 他. 国内初となるHBV genotype HによるB型急性肝炎の1例. 肝臓. 2007; 48: 109-11
|
|
|
|
|
6) Zhang Z, Zhang JY, Wherry EJ, et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology. 2008; 134: 1938-49, 49 e1-3
|
|
|
|
|
|
7) Protzer U, Seyfried S, Quasdorff M, et al. Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology. 2007; 133: 1156-65
|
|
|
|
|
|
8) Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007; 45: 97-101
|
|
|
|
|
|
9) Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008; 148: 519-28
|
|
|
|
|
|
10) Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001; 344: 68-9
|
|
|
|
|
|
11) Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol. 2004; 83: 58-60
|
|
|
|
|
|
12) Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003; 102: 1930
|
|
|
|
|
|
13) Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005; 11: 189-91
|
|
|
|
|
|
14) Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma. 2005; 46: 1085-9
|
|
|
|
|
|
15) Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med. 2006; 45: 721-4
|
|
|
|
|
|
16) Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006; 131: 59-68
|
|
|
|
|
|
17) Liu CJ, Kao JH, Chen DS. Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. Gastroenterology. 2006; 131: 1656. author reply-7
|
|
|
|
|
|
18) Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med. 2006; 45: 747-8
|
|
|
|
|
|
19) Umemura T, Tanaka E, Kiyosawa K, et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008; 47: e52-6
|
|
|
|
|